Story · Medicine & Biotech
Tandem wins FDA clearance for tubeless automated insulin delivery system
4 outlets · first reported by Drug Delivery Business on · latest · 97 hours of coverage · 2 countries
The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.” (MedTech Dive)
Coverage, in order
-
Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
The Mobi with tubed and tubeless options. [Image courtesy of Tandem Diabetes Care] Tandem Diabetes Care (Nasdaq: TNDM) has secured an FDA clearance for a tubeless version of its miniaturized automated insulin delivery system. The Tandem Mobi’s new cartridge and infusion set converts the pump into a…
-
FDA Approves Tubeless Option for Tandem Mobi Insulin PumpThe US FDA has approved a tubeless cartridge and infusion set for the Tandem Mobi insulin pump, offering users the flexibility to choose between tubed and tubeless insulin delivery. The system incorporates Control-IQ+ technology, which predicts glucose levels and automatically adjusts insulin…
-
Tandem wins FDA clearance for tubeless automated insulin delivery systemThe clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.”
-
MiniMed gets FDA nod for tubeless insulin pumpMiniMed will go head to head with Tandem Diabetes Care as both companies debut their first tubeless pumps.
-
FDA clears Tandem Diabetes insulin pump for tubeless insulin deliveryPatients with a Tandem Mobi insulin pump will soon be able to choose between two wear options—tubed and tubeless—with the same device. Tubeless insulin delivery can last up to seven days.
-
MiniMed claims quick FDA clearance for Fit patch pump
The waterproof MiniMed Fit sports a wear time of 7 days. [Image courtesy of MiniMed] After submitting its patch pump for FDA review in late August, MiniMed (Nasdaq: MMED) has turned around a quick clearance for the Fit automated insulin delivery system. The Fit marks the company’s first tubeless…
-
FDA clears MiniMed’s tubeless insulin pumpThe MiniMed Fit is indicated for patients 7 years old and older with type 1 or type 2 diabetes. This represents the second FDA clearance for a tubeless automated insulin delivery system in a matter of days.
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.